Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | ITPR3 | Q14573 | 5/20 | 0.44 |
| ▸ | ITPR2 | Q14571 | 2/20 | 0.44 |
| ▸ | ITPR1 | Q14643 | 2/20 | 0.44 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191662 | 0.84 | SMPD1 (0.50) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL7798872 | 0.84 | SMPD1 (0.50) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL4442196 | 0.84 | SMPD1 (0.50) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL8859419 | 0.82 | ITPR3 (0.52) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL30412792 | 0.82 | ITPR3 (0.52) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL17945370 | 0.82 | AMY1A (0.33) | — | |
| SCHEMBL1104571 | 0.82 | AMY1A (0.41) | — | |
| SCHEMBL17052655 | 0.81 | TLR4 (0.39) | SMPD1 | |
| SCHEMBL17052659 | 0.81 | TLR4 (0.36) | SMPD1 | |
| SCHEMBL25976118 | 0.81 | TLR4 (0.36) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541599-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8153725-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7718810-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7700706-B2 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090286085-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-7427675-B2 | Compounds and methods for the characterization of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080119645-A1 | Immobilization; solid phase synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | LSIS PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7348391-B2 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286085-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | NEFM, NOD2, MACF1 | SMPD1 4794/4885ITPR3 2062/4885ITPR2 2739/4885 |
| US-20090131682-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | SMPD1 4828/4885ITPR3 3456/4885ITPR2 3264/4885 |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | NEFM, NOD2, MACF1 | SMPD1 4794/4885ITPR3 2062/4885ITPR2 2739/4885 |
| US-20120165547-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | SMPD1 4828/4885ITPR3 3456/4885ITPR2 3264/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | SMPD1 4828/4885ITPR3 3456/4885ITPR2 3264/4885 |
| US-20080119645-A1 | Immobilization; solid phase synthesis | RNGTT, NOP2, NSUN2 | SMPD1 4410/4885ITPR3 4401/4885ITPR2 4103/4885 |
| US-20100234528-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | SMPD1 4828/4885ITPR3 3456/4885ITPR2 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.